# PMCB (Pharmacyte Biotech, Inc.) - SEC EDGAR Financial Statements

> Pharmacyte Biotech, Inc. reported $0 in revenue and a net loss of $16.15M for the trailing twelve months ended July 31, 2026.

- Canonical: https://convexityos.com/fundamentals/PMCB
- Markdown: https://convexityos.com/fundamentals/PMCB.md
- SEC CIK: 0001157075
- Reporting currency: USD
- Latest filing period: July 31, 2026
- Last synced: Nov 21, 2026, 05:09 UTC
- Primary source: [SEC EDGAR](https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0001157075&type=&dateb=&owner=include&count=40)

## Key Financial Metrics

| Metric | Period | Value | Notes |
| --- | --- | --- | --- |
| Revenue | TTM | $0 | Jul 31, 2026 |
| Operating Income | TTM | -$7.01M | Operating profit |
| Net Income | TTM | -$16.15M | GAAP bottom line |
| Diluted EPS | TTM | -$1.50 | Split-adjusted |
| Free Cash Flow | TTM | -- | Operating CF less CapEx |
| Cash & ST Investments | Jul 31, 2026 | $17.84M | Total debt: -- |

## Income Statement

### Income Statement (Annual)

| Line Item | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| **Revenue** | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Research & Development | $391K | $438K | $407K | $469K | $691K | $916K | $301K | $460K | $2.00M | $1.18M |
| Total Operating Expenses | $6.85M | $4.38M | $8.52M | $6.46M | $4.39M | $3.62M | $3.83M | $4.10M | $6.98M | $4.44M |
| **Operating Income** | -$6.85M | -$4.38M | -$8.52M | -$6.46M | -$4.39M | -$3.62M | -$3.83M | -$4.10M | -$6.98M | -$4.44M |
| Interest Income | $733K | $1.42M | $3.40M | $1.94M | $158K | $0 | -- | -- | -- | -- |
| Interest Expense | -- | -- | -- | $0 | $509 | $3.0K | $453 | $0 | $0 | $1.5K |
| Income Tax Expense | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| **Net Income** | -$19.42M | $30.66M | $334K | -$4.32M | -$4.24M | -$3.55M | -$3.83M | -$4.07M | -$6.83M | -$4.44M |
| Basic EPS | -$2.77 | $3.19 | -$1.80 | -$0.22 | -$0.27 | -$2.45 | -$4.23 | $0.00 | -$0.01 | -$0.01 |
| **Diluted EPS** | -$2.77 | $3.19 | -$1.80 | -$0.22 | -$0.27 | -$2.45 | -$4.23 | $0.00 | -$0.01 | -$0.01 |
| Basic Shares Outstanding | 8.4M | 7.3M | 9.6M | 19.5M | 15.5M | 1.4M | 903.8K | 1.10B | 968.6M | 845.3M |
| Diluted Shares Outstanding | 8.4M | 7.3M | 9.6M | 19.5M | 15.5M | 1.4M | 903.8K | 1.10B | 968.6M | 845.3M |

### Income Statement (Quarterly)

| Line Item | Jul 2026 | Apr 2026 | Jan 2026 | Oct 2025 | Jul 2025 | Apr 2025 | Jan 2025 | Oct 2024 |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| **Revenue** | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Research & Development | $60K | $62K | $93K | $141K | $95K | $127K | $118K | $97K |
| Total Operating Expenses | $1.01M | $2.51M | $2.12M | $1.38M | $848K | $1.04M | $960K | $1.11M |
| **Operating Income** | -$1.01M | -$2.51M | -$2.12M | -$1.38M | -$848K | -$1.04M | -$960K | -$1.11M |
| Interest Income | $166K | $79K | $231K | $206K | $218K | $230K | $256K | $383K |
| Income Tax Expense | $0 | -- | -- | -- | $0 | -- | -- | -- |
| **Net Income** | -$5.08M | -$4.39M | $747K | -$7.42M | -$8.36M | $11.75M | -$3.05M | -$1.47M |
| Basic EPS | -$0.54 | -- | -$0.17 | -$1.24 | -$1.23 | -- | -$0.44 | -$0.39 |
| **Diluted EPS** | -$0.54 | -- | -$0.17 | -$1.24 | -$1.23 | -- | -$0.44 | -$0.39 |
| Basic Shares Outstanding | 10.7M | -- | 9.3M | 6.8M | 6.8M | -- | 7.0M | 7.6M |
| Diluted Shares Outstanding | 10.7M | -- | 9.3M | 6.8M | 6.8M | -- | 7.0M | 7.6M |

## Balance Sheet

### Balance Sheet (Annual)

| Line Item | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Cash & Cash Equivalents | $18.60M | $15.17M | $50.18M | $68.04M | $85.40M | $2.20M | $895K | $515K | $1.06M | $3.46M |
| Short-Term Investments | $254K | $366K | $0 | -- | -- | -- | -- | -- | -- | -- |
| **Cash & Short-Term Investments** | $18.86M | $15.54M | $50.18M | $68.04M | $85.40M | $2.20M | $895K | $515K | $1.06M | $3.46M |
| **Total Current Assets** | $37.42M | $22.38M | $50.44M | $68.15M | $85.49M | $2.28M | $1.04M | $653K | $1.28M | $3.54M |
| Intangible Assets | $0 | $1.55M | $1.55M | $3.55M | $3.55M | -- | -- | -- | -- | -- |
| Other Non-Current Assets | $7.7K | $7.7K | -- | -- | -- | $7.4K | $7.4K | $7.4K | $7.4K | $7.4K |
| **Total Non-Current Assets** | $9.33M | $32.79M | $9.46M | $5.13M | $5.13M | $5.13M | $5.13M | $5.13M | $5.13M | $5.13M |
| **Total Assets** | $46.75M | $55.17M | $59.90M | $73.28M | $90.62M | $7.40M | $6.17M | $5.78M | $6.41M | $8.67M |
| Accounts Payable | $271K | $399K | $389K | $128K | $205K | $172K | $186K | $122K | $353K | $366K |
| **Total Current Liabilities** | $826K | $2.91M | $7.42M | $587K | $704K | $725K | $1.03M | $743K | $644K | $580K |
| **Total Non-Current Liabilities** | $10.95M | $363K | $12.97M | $0 | $0 | $0 | $46K | $0 | $0 | $0 |
| **Total Liabilities** | $11.77M | $3.28M | $20.39M | $587K | $704K | $725K | $1.08M | $743K | $644K | $580K |
| Common Stock | $2.6K | $2.2K | $2.2K | $2.2K | $2.1K | $159 | $109 | $119K | $101K | $91K |
| Retained Earnings | -$104.4M | -$84.97M | -$115.6M | -$116.0M | -$111.6M | -$107.4M | -$103.9M | -$100.0M | -$95.96M | -$89.14M |
| Accumulated Other Comp. Income | -$21K | -$24K | -$24K | -$23K | -$16K | -$20K | -$22K | -$14K | -$4.7K | $1.7K |
| **Total Stockholders' Equity** | $33.29M | $51.89M | $27.65M | $72.69M | $89.92M | $6.68M | $5.09M | $5.04M | $5.77M | $8.09M |
| Total Equity | $33.29M | $51.89M | $27.65M | $72.69M | $89.92M | $6.68M | $5.09M | $5.04M | $5.77M | $8.09M |

### Balance Sheet (Quarterly)

| Line Item | Jul 2026 | Apr 2026 | Jan 2026 | Oct 2025 | Jul 2025 | Apr 2025 | Jan 2025 | Oct 2024 |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Cash & Cash Equivalents | $17.74M | $18.60M | $20.17M | $15.41M | $13.18M | $15.17M | $16.38M | $20.84M |
| Short-Term Investments | $99K | $254K | $372K | $201K | $262K | $366K | $373K | -- |
| **Cash & Short-Term Investments** | $17.84M | $18.86M | $20.54M | $15.61M | $13.44M | $15.54M | $16.76M | $20.84M |
| **Total Current Assets** | $30.97M | $37.42M | $20.70M | $23.02M | $19.11M | $22.38M | $16.96M | $21.33M |
| Intangible Assets | -- | $0 | $1.55M | $1.55M | $1.55M | $1.55M | $1.55M | $1.55M |
| Other Non-Current Assets | $7.7K | $7.7K | -- | -- | -- | $7.7K | -- | -- |
| **Total Non-Current Assets** | $5.74M | $9.33M | $35.18M | $32.95M | $26.00M | $32.79M | $26.87M | $33.77M |
| **Total Assets** | $36.71M | $46.75M | $55.87M | $55.98M | $45.11M | $55.17M | $43.83M | $55.10M |
| Accounts Payable | $391K | $271K | $1.20M | $1.02M | $465K | $399K | $485K | $349K |
| **Total Current Liabilities** | $769K | $826K | $1.68M | $1.58M | $1.06M | $2.91M | $1.19M | $4.78M |
| **Total Non-Current Liabilities** | $6.13M | $10.95M | $14.79M | $17.84M | $458K | $363K | $2.38M | $6.87M |
| **Total Liabilities** | $6.90M | $11.77M | $16.47M | $19.42M | $1.52M | $3.28M | $3.58M | $11.65M |
| Common Stock | $2.6K | $2.6K | $2.6K | $2.2K | $2.2K | $2.2K | $2.2K | $2.2K |
| Retained Earnings | -$109.5M | -$104.4M | -$100.0M | -$100.7M | -$93.33M | -$84.97M | -$96.72M | -$93.67M |
| Accumulated Other Comp. Income | -$21K | -$21K | -$22K | -$24K | -$24K | -$24K | -$24K | -$23K |
| **Total Stockholders' Equity** | $27.51M | $33.29M | $38.11M | $35.24M | $43.59M | $51.89M | $40.25M | $43.45M |
| Total Equity | $27.51M | $33.29M | $38.11M | $35.24M | $43.59M | $51.89M | $40.25M | $43.45M |

## Cash Flow Statement

### Cash Flow Statement (Annual)

| Line Item | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Net Income | -$19.42M | $30.66M | $334K | -$4.32M | -$4.24M | -$3.55M | -$3.83M | -$4.07M | -$6.83M | -$4.44M |
| Stock-Based Compensation | $892K | $0 | $675K | $7.3K | $33K | $194K | $369K | $293K | $580K | $420K |
| Change in Payables | -- | -- | -- | -$243K | $33K | -$14K | $64K | -$231K | -$13K | $30K |
| **Operating Cash Flow** | -$5.15M | -$2.98M | -$2.15M | -$3.79M | -$4.12M | -$3.33M | -$2.34M | -$2.88M | -$5.08M | -$3.34M |
| Purchases of Investments | -- | -$7.00M | $0 | -- | -- | -- | -- | -- | -- | -- |
| **Investing Cash Flow** | $2.00M | -$7.00M | -$5.00M | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Common Stock Issued | -- | -- | -- | $0 | $87.36M | $4.70M | $2.66M | $2.34M | $2.68M | $4.88M |
| Share Repurchases | -$402K | -$2.54M | -$28.20M | -$13.56M | $0 | -- | -- | -- | -- | -- |
| **Financing Cash Flow** | $6.58M | -$25.03M | -$10.71M | -$13.56M | $87.31M | $4.64M | $2.73M | $2.34M | $2.68M | $4.88M |
| **Net Change in Cash** | $3.43M | -$35.01M | -$17.86M | -$17.36M | $83.20M | $1.31M | $380K | -- | -- | -- |

### Cash Flow Statement (Quarterly)

| Line Item | Jul 2026 | Apr 2026 | Jan 2026 | Oct 2025 | Jul 2025 | Apr 2025 | Jan 2025 | Oct 2024 |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Net Income | -$5.08M | -$4.39M | $747K | -$7.42M | -$8.36M | $11.75M | -$3.05M | -$1.47M |
| Stock-Based Compensation | -- | $0 | $772K | $60K | $60K | $0 | -$342K | $119K |
| **Operating Cash Flow** | -$781K | -$1.39M | -$787K | -$980K | -$1.99M | -$1.04M | -$510K | -$1.05M |
| Purchases of Investments | -- | -- | -- | -$3.00M | $0 | $0 | $0 | $0 |
| **Investing Cash Flow** | -- | $0 | $5.00M | -$3.00M | $0 | $0 | $0 | $0 |
| Share Repurchases | -- | $0 | -$402K | $0 | $0 | -$172K | -$225K | -$1.40M |
| **Financing Cash Flow** | -$83K | -$170K | $544K | $6.21M | $0 | -$172K | -$3.95M | -$10.74M |
| **Net Change in Cash** | -$865K | -$1.56M | $4.76M | $2.23M | -$1.99M | -$1.21M | -$4.46M | -$11.80M |

## Profitability Ratios & YoY Growth

### Profitability Ratios & YoY Growth (Annual)

| Line Item | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Return on Equity (ROE) | -58.3% | 59.1% | 1.2% | -5.9% | -4.7% | -53.2% | -75.2% | -80.7% | -118.4% | -54.9% |
| Return on Assets (ROA) | -41.5% | 55.6% | 0.6% | -5.9% | -4.7% | -48.0% | -62.1% | -70.3% | -106.5% | -51.3% |
| Current Ratio | 45.28x | 7.68x | 6.80x | 116.18x | 121.38x | 3.14x | 1.01x | 0.88x | 1.99x | 6.10x |
| Quick Ratio | 22.82x | 5.33x | 6.76x | 115.99x | 121.24x | 3.04x | 0.87x | 0.69x | 1.65x | 5.97x |
| **Net Income Growth (YoY)** | -163.4% | +9085.0% | -- | -- | -- | -- | -- | -- | -- | -- |
| EPS Growth (YoY) | -186.8% | -- | -- | -- | -- | -- | -- | -- | -- | -- |
| 5Y Revenue / Share Growth | -- | -- | -- | -- | -- | -- | -- | -- | -100.0% | -100.0% |
| 10Y Revenue / Share Growth | -- | -- | -- | -100.0% | -100.0% | -100.0% | -- | -- | -- | -- |

### Profitability Ratios & YoY Growth (Quarterly)

| Line Item | Jul 2026 | Apr 2026 | Jan 2026 | Oct 2025 | Jul 2025 | Apr 2025 | Jan 2025 | Oct 2024 |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Return on Equity (ROE) | -58.7% | -58.3% | -8.6% | -20.1% | -2.6% | 59.1% | 50.3% | 52.2% |
| Return on Assets (ROA) | -44.0% | -41.5% | -5.9% | -12.6% | -2.5% | 55.6% | 46.2% | 41.2% |
| Current Ratio | 40.30x | 45.28x | 12.33x | 14.60x | 18.01x | 7.68x | 14.20x | 4.47x |
| Quick Ratio | 23.21x | 22.82x | 12.24x | 9.89x | 12.67x | 5.33x | 14.03x | 4.36x |
| **Net Income Growth (YoY)** | -- | -137.4% | -- | -- | -135.7% | +772.5% | -- | -152.7% |
| EPS Growth (YoY) | -- | -- | -- | -- | -164.7% | -- | -- | -- |

## Related Companies

[AMZN (Amazon.com, Inc.)](https://convexityos.com/fundamentals/AMZN), [WMT (Walmart Inc.)](https://convexityos.com/fundamentals/WMT), [AAPL (Apple Inc.)](https://convexityos.com/fundamentals/AAPL), [GOOG (Alphabet Inc.)](https://convexityos.com/fundamentals/GOOG), [UNH (UnitedHealth Group Incorporated)](https://convexityos.com/fundamentals/UNH), [CVS (CVS HEALTH Corp)](https://convexityos.com/fundamentals/CVS), [MCK (McKESSON CORPORATION)](https://convexityos.com/fundamentals/MCK), [BRK-A (Berkshire Hathaway Inc.)](https://convexityos.com/fundamentals/BRK-A)

---

## About Convexity

Published by [Convexity](https://convexityos.com/), a primary-source financial intelligence terminal built on SEC EDGAR filings, XBRL financial statements, options, macro data, and cited AI research. Free tier with no card and published prices at https://convexityos.com/pricing; Streamable HTTP MCP server at https://convexityos.com/mcp; full site index at https://convexityos.com/llms.txt.
